Importantly, following the manufacturer's instructions (MCE), treatment with stattic (2 μmol/L), a STAT3 inhibitor, markedly abolished the ability of SPARC overexpression to promote HK2 expression in CRC cells (Figure 5B). Here, SPARC is linked to colorectal carcinoma.